發(fā)布時(shí)間：2018-07-10 15:59

  本文選題：干眼癥 + 眼部炎癥��； 參考：《中國新藥雜志》2017年11期

【摘要】：lifitegrast是一種新型小分子T細(xì)胞抑制劑,通過影響細(xì)胞粘附分子(ICAM-1)與淋巴細(xì)胞功能相關(guān)抗原(LFA-1)的結(jié)合,有效阻斷炎癥通路,抑制T細(xì)胞介導(dǎo)的炎癥反應(yīng),從而改善干眼癥患者的癥狀與體征。多項(xiàng)動物試驗(yàn)及臨床研究顯示,lifitegrast具有良好的安全性和耐受性。2016年7月美國FDA批準(zhǔn)其上市,用于干眼癥的治療。本文對其藥理作用、藥動學(xué)、臨床研究及安全性等進(jìn)行綜述。
[Abstract]:Lifitegrast is a new type of small molecule T cell inhibitor. By affecting the binding of ICAM-1 to lymphocyte function related antigen (LFA-1), lifitegrast effectively blocks the inflammatory pathway and inhibits the inflammatory response mediated by T cells. So as to improve the symptoms and signs of patients with xerophthalmia. A number of animal trials and clinical studies have shown that lifitegrast is safe and well tolerated. In July 2016, the FDA approved its launch for dry eye treatment. The pharmacological action, pharmacokinetics, clinical research and safety of the drug were reviewed in this paper.
【作者單位】： 上海交通大學(xué)醫(yī)學(xué)院附屬仁濟(jì)醫(yī)院藥學(xué)部;
【分類號】：R988.1
，

本文編號：2113880